A1c

Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at...


Cardiovascular autonomic diabetic neuropathy ( CAN ) is a serious complication of diabetes. No reliable data on the prevalence of...


Omarigliptin, an investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, has achieved its primary efficacy endpoint...


Although assessment of cardiovascular safety is mandated by regulatory agencies for the development of new drugs to treat type 2...


Metabolic surgery is a novel therapy for mild obesity ( BMI 30-35 Kg/m2 ) in type 2 diabetes mellitus (...


Type 2 diabetes and obesity impair kidney function. Researchers have examined their respective contributions to urinary albumin excretion ( UAE...


The results from SUSTAIN-1, the first phase 3a trial for Semaglutide, a new GLP-1 analogue administered once-weekly were presented. The...


Empagliflozin is an oral selective SGLT-2 inhibitor that acts by blocking the reabsorption of glucose in the proximal tubules in...


The aim was to assess the efficacy and safety of Dapagliflozin ( Forxiga ) as add-on therapy in patients with...


About 60% of patients with type 2 diabetes mellitus achieve remission after Roux-en-Y gastric bypass ( RYGB ) surgery. No...


Researchers have compared stepwise addition of bolus Insulin with a full basal-bolus regimen in patients with type 2 diabetes inadequately...


Although carbohydrate counting is the recommended dietary strategy for achieving glycaemic control in people with type 1 diabetes mellitus, the...


There are limited data about the effects of sodium glucose cotransporter 2 inhibitors when used with insulin. The efficacy and...


Combination treatment with a glucagon-like peptide-1 ( GLP-1 ) agonist and basal Insulin has been proposed as a treatment strategy...


When patients with type 2 diabetes mellitus start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 ( GLP-1...


Metformin ( Glucophage ) is a first-line oral agent used in the treatment of type 2 diabetes mellitus, but glycaemic...


The FDA ( Food and Drug Administration ) has approved Myalept ( Metreleptin for injection ) as replacement therapy to...


Results from an observational study that has assessed the differences in time to initiation of Insulin use and the proportion...


New research published in Diabetologia, the journal of the European Association for the Study of Diabetes ( EASD ), has...


Liraglutide is a human glucagon-like peptide 1 analog that may be administered once a day because of its prolonged half-life...